» Articles » PMID: 9763107

Management of Possible Sexual, Injecting-drug-use, or Other Nonoccupational Exposure to HIV, Including Considerations Related to Antiretroviral Therapy. Public Health Service Statement. Centers for Disease Control and Prevention

Overview
Journal MMWR Recomm Rep
Specialty Public Health
Date 1998 Oct 8
PMID 9763107
Citations 11
Affiliations
Soon will be listed here.
Abstract

The most effective methods for preventing human immunodeficiency virus (HIV) infection are those that protect against exposure to HIV. Preventive behaviors include sexual abstinence, sex only with an uninfected partner, consistent and correct condom use, abstinence from injecting-drug use, and consistent use of sterile equipment by those unable to cease injecting-drug use. Some healthcare providers have proposed offering antiretroviral drugs to persons with unanticipated sexual or injecting-drug-use HIV exposure to prevent transmission. However, because no data exist regarding the efficacy of this therapy for persons with nonoccupational HIV exposure, it should be considered an unproven clinical intervention. Health-care providers and their patients may opt to consider using antiretroviral drugs after nonoccupational HIV exposures that carry a high risk for infection, but only after careful consideration of the potential risks and benefits and with a full awareness of the gaps in current knowledge. To address concerns related to providing antiretroviral agents to persons after nonoccupational HIV exposure, CDC convened a meeting in July 1997 of scientists, public health experts, clinicians, members of professional associations, representatives from industry, ethicists, and members of affected communities. This report reviews the topics raised at the meeting, provides background information on patient management options, and presents considerations for antiretroviral therapy.

Citing Articles

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP).

Inciarte A, Ugarte A, Martinez-Rebollar M, Torres B, Fernandez E, Berrocal L Open Forum Infect Dis. 2023; 10(8):ofad374.

PMID: 37539061 PMC: 10394723. DOI: 10.1093/ofid/ofad374.


"It's Like Plan B but for HIV!" Design and Evaluation of a Media Campaign to Drive Demand for PEP.

Fagan J, Frye V, Calixte R, Jain S, Molla L, Lawal A AIDS Behav. 2020; 24(12):3337-3345.

PMID: 32390059 PMC: 7882212. DOI: 10.1007/s10461-020-02906-1.


The Link Between HIV Knowledge and Prophylaxis to Health Professionals.

Cake A, Mihani J, Stroni G, Stroni R, Avdaj A Open Access Maced J Med Sci. 2019; 7(8):1396-1400.

PMID: 31110592 PMC: 6514330. DOI: 10.3889/oamjms.2019.266.


Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County.

Beymer M, Kofron R, Tseng C, Bolan R, Flynn R, Sayles J Int J STD AIDS. 2017; 29(6):557-562.

PMID: 29183270 PMC: 5843554. DOI: 10.1177/0956462417743158.


Differentiating Nonoccupational Postexposure Prophylaxis Seroconverters and Non-Seroconverters in a Community-Based Clinic in Los Angeles, California.

Beymer M, Weiss R, Bolan R, Kofron R, Flynn R, Pieribone D Open Forum Infect Dis. 2017; 4(2):ofx061.

PMID: 28596981 PMC: 5458294. DOI: 10.1093/ofid/ofx061.